Additional file 1 of Psychometric evaluation of the Chinese version of advance care planning self-efficacy scale among clinical nurses

Additional file 1

Pervasive Parallelism in Highly-Trustable Interactive Theorem Proving Systems

International audienc

The effects of LPM570065, desvenlafaxine and vehicle on the extracellular monoamine levels after chronic administration.

<p>The effects of LPM570065 (black line), desvenlafaxine (red line) and vehicle (blue line) on the extracellular 5-HT, DA and NE levels in the rat striatum after chronic administration (oral suspension: 0.06 mmol·kg⁻¹·day⁻¹ for 14 days) are indicated in (A), (B) and (C), respectively. LPM570065, desvenlafaxine or vehicle was administered at time 0 min. Data are presented as the mean±SD, n = 7–8; ***<i>p</i><0.001 LPM570065 vs. vehicle; <i>^###p</i><0.001 desvenlafaxine vs. vehicle; two-way ANOVA with repeated measures. (D) The overall effects on the extracellular 5-HT, DA and NE levels in the rat striatum following the chronic treatment with LPM570065 (black column), desvenlafaxine (red column) or vehicle (blue column). The columns represent the AUC_{0-t min} values calculated as the differences in relative changes in the extracellular monoamine levels over a period between the drug-treated and vehicle-treated groups (t = 240 min for 5-HT and NE; t = 160 min for DA). Data are presented as the mean±SD, n = 7–8; ***<i>p</i><0.001 drug vs. vehicle; one-way ANOVA.</p

Basal extracellular levels of 5-HT, DA and NE.

a<p>n = 8 adult male Sprague-Dawley rats.</p>b<p>n = 7 adult male Sprague-Dawley rats.</p

Forced swim test in rats for evaluating antidepressant-like activity of LPM570065 and desvenlafaxine.

<p>The effects of LPM570065 (black column), desvenlafaxine (red column) and vehicle (blue column) on the immobility time in the forced swim test over a 4-h post-dosing period are indicated as follows: (A) for acute administration and (B) for chronic administration. Acute (0.06 mmol·kg⁻¹) and chronic (0.06 mmol·kg⁻¹·day⁻¹ for 14 days) administration were performed by providing rats the oral suspensions of LPM570065 and desvenlafaxine. At 0.5, 1, 2 and 4 h post-dosing, rats were placed in the cylinder again for 5 min (test session), and the total duration of immobilization was recorded. Data are presented as the mean±SD (n = 10) in the form of a histogram; ***<i>p</i><0.001, **<i>p</i><0.01, *<i>p</i><0.05 drug vs. relative vehicle; one-way ANOVA, Bonferroni’s post-test.</p

The chemical structure of LPM570065.

<p>The chemical structure of LPM570065.</p

LPM570065 and desvenlafaxine concentrations in the rat striatum after administration.

<p>A single dose of LPM570065 or desvenlafaxine was administered by using different administration routes (blue: 0.06 mmol·kg⁻¹ for oral solution; black: 0.06 mmol·kg⁻¹ for oral suspension; red: 0.04 mmol·kg⁻¹ for intravenous solution). All data are presented as the mean±SD, n = 6 rat per time point. (A) LPM570065 concentrations after administration of LPM570065 using different administration routes. The small graphic in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0091775#pone-0091775-g003" target="_blank">Figure 3A</a> presents a partially enlarged detail of the LPM570065 concentrations using different administration routes. (B) Desvenlafaxine concentrations after LPM570065 administration using different administration routes. (C) Desvenlafaxine concentrations after the administration of desvenlafaxine using different administration routes. (D) Total exposure of LPM570065 and desvenlafaxine in the rat striatum over a 4-h period after administration of LPM570065 or desvenlafaxine using different administration routes. Total exposure is expressed as the area under the curve (AUC_{0–240 min}) of LPM570065 and desvenlafaxine in the form of a histogram.</p

Fecal microbial ecology is altered in cancer patients prior to radiotherapy.

<p>Differences in microbial alpha diversity between healthy controls and cancer patients prior to radiotherapy who did or did not develop diarrhea is indicated by Shannon’s diversity index (A) and Chao1 species richness (B). (C) <i>Firmicutes/Bacteroides</i> ratio in the same groups of patients. * and ^# indicate statistically significant differences at <i>p</i><0.05 and 0.01, respectively (ANOVA followed by Tukey post-hoc test).</p

The microdialysis study design after acute and chronic drug administration.

<p>The microdialysis study design after acute and chronic drug administration.</p

Pyrosequencing data summary.

<p>Pyrosequencing data summary.</p